Purpose: EGFR and anaplastic lymphoma kinase (ALK) alterations have been regarded as oncogenic drivers and incorporated into clinical practices to manage nonsmall cell lung cancer (NSCLC). Alterations of these two genes were traditionally considered to be mutually exclusive, but recent studies have suggested that they can occur concomitantly. Here, we investigated the prevalence, clinical features and outcomes in response to the treatment of NSCLC patients who harbor EGFR and ALK co-alterations. Conclusion: EML4-ALK/EGFR and non-EML4-ALK/EGFR co-alterations displayed distinct clinical features and responses to EGFR-TKIs, suggesting that non-EML4-ALK co-alterations are likely to occur as a resistance mechanism to EGFR-TKI. In addition, dual-TKI therapy might be a better choice than single-TKI treatments for these co-altered patients. To the best of our knowledge, this is the largest dual-positive EGFR/ALK cohort study in People's Republic of China. READ ARTICLE
Drug Design and Development Therapies DOI:10.2147/DDDT.S196189
Authors: Jixian Liu, Zhimin Mu, Li Liu, Kang Li, Richeng Jiang, Peng Chen, Qiang Zhou, Meiling Jin, Yuxiang Ma, Yuancai Xie, Jianxing Xiang, Bing Li, Yafeng Ma, Xinru Mao, Lu Zhang, Tengfei Zhang, Da Wu